



## Clinical trial results:

**A Phase II, single arm, multicenter, open-label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (BIANCA)**

**Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.nov> for complete trial results**

### Summary

EudraCT number	2017-005019-15
Trial protocol	ES FR DE SE DK NO AT GB NL FI IT
Global end of trial date	26 April 2023

### Results information

Result version number	v1 (current)
This version publication date	10 November 2023
First version publication date	10 November 2023

### Trial information

#### Trial identification

Sponsor protocol code	CCTL019C2202
-----------------------	--------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03610724
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Novartis Pharma, AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma, AG, 41 613241111, <a href="mailto:novartis.email@novartis.com">novartis.email@novartis.com</a>
Scientific contact	Clinical Disclosure Office, Novartis Pharma, AG, 41 613241111, <a href="mailto:novartis.email@novartis.com">novartis.email@novartis.com</a>

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001654-PIP02-17

Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 April 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 April 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective was to evaluate the efficacy of tisagenlecleucel therapy as measured by ORR and determined by local investigator assessments in subjects with aggressive r/r B-cell NHL.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 February 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 2
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Denmark: 1
Country: Number of subjects enrolled	Finland: 1
Country: Number of subjects enrolled	France: 4
Country: Number of subjects enrolled	Germany: 1
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Japan: 4
Country: Number of subjects enrolled	Netherlands: 2
Country: Number of subjects enrolled	Norway: 2
Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	United Kingdom: 4

Country: Number of subjects enrolled	United States: 7
Worldwide total number of subjects	33
EEA total number of subjects	14

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	11
Adolescents (12-17 years)	18
Adults (18-64 years)	4
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted in twenty-four centers across 14 countries. Although 34 participants met the eligibility criteria and apheresis was accepted by the manufacturing facility, only 33 were infused in the study.

### Pre-assignment

Screening details:

Consent, Screening, Pre-treatment, Treatment and Follow-up. In the Pretreatment phase, the subject may have undergone optional bridging therapy or lymphodepleting chemotherapy.

Full Analysis Set: 33

Efficacy Analysis Set (EAS): 28; 4 patients with Complete Response prior to infusion & 1 without a scan prior to infusion excluded from EAS.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Tisagenlecleucel
-----------	------------------

Arm description:

These participants were infused once with CAR-positive viable T cells.

Arm type	Experimental
Investigational medicinal product name	Tisagenlecleucel
Investigational medicinal product code	CTL019
Other name	
Pharmaceutical forms	Blood fraction modifier
Routes of administration	Intravenous use

Dosage and administration details:

Tisagenlecleucel was administered once as an intravenous infusion, at a dose of either 0.2 to 5 x 10<sup>6</sup> CAR-positive viable T cells per kg body weight for subjects ≤ 50 kg or 0.1 to 2.5 x 10<sup>8</sup> CARpositive viable T cells for subjects > 50 kg

Investigational medicinal product name	lymphodepleting chemotherapy
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

lymphodepletion with recommended Fludarabine (30 mg/m<sup>2</sup> IV daily for 4 days) and cyclophosphamide (500 mg/m<sup>2</sup> IV daily for 2 days starting with the first dose of fludarabine) (unless contra-indicated for subject)

Investigational medicinal product name	Bridging Therapy
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Pre-treatment phase could also include bridging therapy of investigator's choice

<b>Number of subjects in period 1</b>	Tisagenlecleucel
Started	33
Met Eligibility criteria and were infused	33
Met Eligibility criteria, not infused*	1
Completed treatment & primary f/u phase	14
Discont. treatment & primary f/u phase	19
Completed	14
Not completed	19
Adverse event, serious fatal	17
Physician decision	1
Lost to follow-up	1

## Baseline characteristics

### Reporting groups

Reporting group title	Tisagenlecleucel
-----------------------	------------------

Reporting group description:

These participants were infused once with CAR-positive viable T cells.

Reporting group values	Tisagenlecleucel	Total	
Number of subjects	33	33	
Age categorical			
Units: Subjects			
Children (2-11 years)	11	11	
Adolescents (12-17 years)	18	18	
Adults (18-64 years)	4	4	
Age Continuous			
Units: years			
median	12.8		
standard deviation	± 4.98	-	
Sex: Female, Male			
Units: Participants			
Female	10	10	
Male	23	23	
Race/Ethnicity, Customized			
Units: Subjects			
White	28	28	
Black or African American	1	1	
Asian	2	2	
Missing	2	2	

## End points

### End points reporting groups

Reporting group title	Tisagenlecleucel
Reporting group description: These participants were infused once with CAR-positive viable T cells.	

### Primary: Overall response rate (ORR) as determined by local investigator

End point title	Overall response rate (ORR) as determined by local investigator <sup>[1]</sup>
-----------------	--

End point description:

The overall response rate (ORR) is defined as the percentage of subjects with a best overall disease response of complete response (CR) or partial response (PR), where the best overall disease response is defined as the best disease response recorded from tisagenlecleucel infusion until progressive disease or start of new anticancer therapy, whichever comes first.

End point type	Primary
----------------	---------

End point timeframe:

any time post-tisagenlecleucel infusion until progressive disease, start of new anticancer therapy, discontinuation or end of study (2 years after last patient first visit), up to 4 years

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analysis was done.

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: Percentage of participants				
number (confidence interval 95%)	32.1 (15.9 to 52.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Event free survival (EFS)

End point title	Event free survival (EFS)
-----------------	---------------------------

End point description:

Event free survival (EFS) is defined as the time from date of first tisagenlecleucel infusion to the earliest date of death from any cause, disease progression as determined by local investigator assessments, or starting new anticancer therapy for underlying cancer, excluding hematopoietic stem cell transplant (HSCT).

End point type	Secondary
----------------	-----------

End point timeframe:

Through study completion, up to 4 years

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: months				
median (confidence interval 95%)	2.1 (1.1 to 2.8)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Duration of response (DOR)

End point title	Duration of response (DOR)
End point description: Duration of response (DOR) is defined as the time from the date of first documented disease response (CR or PR) as determined by local investigator assessments to the date of first documented progression or death due to underlying cancer.	
End point type	Secondary
End point timeframe: Through study completion, up to 4 years	

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: months				
median (confidence interval 95%)	9 (1.0 to 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Progression free survival (PFS)

End point title	Progression free survival (PFS)
End point description: Progression free survival (PFS) is defined as the time from the date of first tisagenlecleucel infusion to the date of first documented disease progression as determined by local investigator assessments or death due to any cause.	
End point type	Secondary
End point timeframe: Through study completion, up to 4 years	



<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: months				
median (confidence interval 95%)	2.5 (1.1 to 2.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Relapse free survival (RFS)

End point title	Relapse free survival (RFS)
End point description: Relapse free survival (RFS) is defined as the time from the date of first documented disease response (CR or PR) as determined by local investigator assessments to the date of first documented disease progression or death due to any cause.	
End point type	Secondary
End point timeframe: Through study completion, up to 4 years	

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: months				
median (confidence interval 95%)	9 (1.0 to 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Overall survival (OS)

End point title	Overall survival (OS)
End point description: Overall survival (OS) is defined as the time from date of first tisagenlecleucel infusion to the date of death due to any cause.	
End point type	Secondary
End point timeframe: Through study completion, up to 4 years	

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	28			
Units: months				
median (confidence interval 95%)	10.4 (3.4 to 999)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Cellular kinetics parameter: Tlast

End point title	Cellular kinetics parameter: Tlast
End point description: The time of last observed quantifiable transgene level in peripheral blood. Pharmacokinetics of tisagenlecleucel were based on chimeric antigen receptor (CAR) transgene levels in peripheral blood as detected by qPCR, unless otherwise noted.	
End point type	Secondary
End point timeframe: Through study completion, up to 4 years	

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	30			
Units: days				
median (full range (min-max))	40.0 (13.0 to 1090)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Cellular kinetics parameter: Tmax

End point title	Cellular kinetics parameter: Tmax
End point description: The time to reach maximum (peak) transgene level (days) in peripheral blood or other body fluid after single dose administration. Pharmacokinetics of tisagenlecleucel were based on chimeric antigen receptor (CAR) transgene levels in peripheral blood as detected by qPCR, unless otherwise noted.	
End point type	Secondary

End point timeframe:

Through study completion, up to 4 years

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	31			
Units: days				
median (full range (min-max))	12.7 (1.90 to 21.9)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Levels of pre-existing and treatment induced humoral immunogenicity and cellular immunogenicity against tisagenlecleucel cellular kinetics, safety and efficacy

End point title	Levels of pre-existing and treatment induced humoral immunogenicity and cellular immunogenicity against tisagenlecleucel cellular kinetics, safety and efficacy
-----------------	---

End point description:

The humoral immunogenicity assay measures the antibody titers specific to tisagenlecleucel prior to and following infusion by flow cytometry. A subject was only defined as positive for tisagenlecleucel treatment-induced or -boosted anti-mCAR19 antibodies when the anti-mCAR19 antibody median fluorescence intensity at any time post-infusion was at least 2.28-fold higher (for samples analyzed on or prior to 05-May-2021) or 2.38-fold higher (for samples analyzed on or after 06-May-2021) than pre-infusion levels for participants whose baseline status was positive (boosted) or if the baseline status was negative but any post-baseline interpretation was positive (induced).

End point type	Secondary
----------------	-----------

End point timeframe:

Until disease progression or through study completion, up to 4 years

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Percentage of participants				
number (not applicable)				
anti-tisagenlecleucel antibodies (+ve) at baseline	87.9			
anti-tisa antibodies (+ve) anytime post-baseline	97.0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Cellular kinetics parameter: Clast

End point title	Cellular kinetics parameter: Clast
-----------------	------------------------------------

End point description:

The last observed quantifiable transgene level in peripheral blood. Pharmacokinetics of tisagenlecleucel were based on chimeric antigen receptor (CAR) transgene levels in peripheral blood as detected by qPCR, unless otherwise noted.

End point type	Secondary
----------------	-----------

End point timeframe:

Through study completion, up to 4 years

End point values	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	30			
Units: copies/ $\mu$ g				
geometric mean (geometric coefficient of variation)	344 ( $\pm$ 350.4)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Cellular kinetics parameter: AUC0-28d

End point title	Cellular kinetics parameter: AUC0-28d
-----------------	---------------------------------------

End point description:

Area Under the Concentration-time Curve (AUs) from the time course of transgene levels in peripheral blood following tisagenlecleucel infusion (days\*copies/ $\mu$ g), from day of infusion to day 28. D28 refers to the timepoint for definition of responder populations. Pharmacokinetics of tisagenlecleucel were based on chimeric antigen receptor (CAR) transgene levels in peripheral blood as detected by qPCR, unless otherwise noted.

End point type	Secondary
----------------	-----------

End point timeframe:

Through study completion, up to 4 years

End point values	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	27			
Units: copies/ $\mu$ g*days				
geometric mean (geometric coefficient of variation)	53500 ( $\pm$ 154.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Cellular kinetics parameter: Cmax

End point title	Cellular kinetics parameter: Cmax
-----------------	-----------------------------------

End point description:

The maximum (peak) transgene level (copies/μg) observed in peripheral blood or other body fluid after single dose administration as measured by qPCR. Pharmacokinetics of tisagenlecleucel were based on chimeric antigen receptor (CAR) transgene levels in peripheral blood as detected by qPCR, unless otherwise noted. Pharmacokinetics of tisagenlecleucel were based on chimeric antigen receptor (CAR) transgene levels in peripheral blood as detected by qPCR, unless otherwise noted.

End point type	Secondary
----------------	-----------

End point timeframe:

Through study completion, up to 4 years

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	31			
Units: copies/μg				
geometric mean (geometric coefficient of variation)	5140 (± 238.9)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of participants who proceeded to stem cell transplant (SCT) after tisagenlecleucel infusion

End point title	Percentage of participants who proceeded to stem cell transplant (SCT) after tisagenlecleucel infusion
-----------------	--

End point description:

These participants proceeded to transplant any time post-tisagenlecleucel therapy until end of study (EOS).

End point type	Secondary
----------------	-----------

End point timeframe:

Through study completion, up to 4 years

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Percentage of participants				
number (not applicable)	21.2			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Positive Predictive Value (PPV)

End point title	Maximum Positive Predictive Value (PPV)
End point description:	
Retrospective assessment of potential cytokine release syndrome (CRS) predictive models considering also data from other CTL019 trials. The Positive Predictive Value (PPV) is the percentage of participants who actually had severe CRS out of all the cases where the prediction model predicts that severe CRS will occur. The maximum PPV is the highest value attained across all potential CRS predictive models.	
End point type	Secondary
End point timeframe:	
Through study completion, up to 4 years	

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Percentage of participants				
number (not applicable)	36.0			

## Statistical analyses

No statistical analyses for this end point

## Post-hoc: All Collected Deaths

End point title	All Collected Deaths
End point description:	
On-treatment deaths were collected during the pos-infusion period starting at the day of first infusion until the end of the study, up to 48 months. All deaths is the sum of pre-infusion and post-infusion deaths.	
Note: 33 patients were infused with tisagenlecleucel. The one death prior to infusion is an additional patient who was enrolled but not infused and is not part of the 33 infused patients.	
End point type	Post-hoc
End point timeframe:	
Pre-treatment deaths: from enrollment to pre-infusion; On-treatment deaths: post-infusion up to 48 months	

<b>End point values</b>	Tisagenlecleucel			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Participants				
On-treatment deaths incl post-infusion deaths	17			
Deaths prior to infusion	1			
All Deaths	18			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

AEs: collected during the post-infusion period, starting at the day of 1st infusion until the end of the study, up to max. duration of 48 months for each patient.

Deaths: collected at all points post-infusion until patients completed the study (LPLV).

Adverse event reporting additional description:

Any sign or symptom that occurs during the post-infusion period (starting at the day of first infusion of CTL019 until the end of the study) and safety follow-up. Deaths in the post treatment survival follow-up are not considered Adverse Events while still included in the All-Cause Mortality table.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	26.0

### Reporting groups

Reporting group title	Tisagenlecleucel - All patients
-----------------------	---------------------------------

Reporting group description:

These participants were infused once with CAR-positive viable T cells.

Serious adverse events	Tisagenlecleucel - All patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	24 / 33 (72.73%)		
number of deaths (all causes)	17		
number of deaths resulting from adverse events	0		
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Condition aggravated			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Disease progression			



subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pyrexia			
subjects affected / exposed	7 / 33 (21.21%)		
occurrences causally related to treatment / all	4 / 7		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	8 / 33 (24.24%)		
occurrences causally related to treatment / all	8 / 8		
deaths causally related to treatment / all	0 / 0		
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumothorax			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Respiratory distress			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Investigations			
Ejection fraction decreased			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutrophil count decreased			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac arrest			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Seizure			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Peripheral sensorimotor neuropathy			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Motor dysfunction			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Aphasia			

subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Depressed level of consciousness			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 1		
Disturbance in attention			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hemiparesis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Memory impairment			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Vision blurred			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Dental caries			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Large intestinal obstruction			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Proctitis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Aspergillus infection			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pseudomonas infection			

subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Candida infection			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Urinary tract infection			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Vascular device infection			
subjects affected / exposed	1 / 33 (3.03%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Tisagenlecleucel - All patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	33 / 33 (100.00%)		
Vascular disorders			
Hypotension			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Haematoma			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Hypertension			

subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
General disorders and administration site conditions			
Catheter site pain			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	3		
Chills			
subjects affected / exposed	4 / 33 (12.12%)		
occurrences (all)	4		
Fatigue			
subjects affected / exposed	5 / 33 (15.15%)		
occurrences (all)	5		
Generalised oedema			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Oedema peripheral			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Pain			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Pyrexia			
subjects affected / exposed	14 / 33 (42.42%)		
occurrences (all)	25		
Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	16 / 33 (48.48%)		
occurrences (all)	19		
Drug hypersensitivity			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Hypogammaglobulinaemia			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	4		
Respiratory, thoracic and mediastinal disorders			

Cough subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 5		
Epistaxis subjects affected / exposed occurrences (all)	4 / 33 (12.12%) 4		
Pleural effusion subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Tachypnoea subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Depression subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Insomnia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 8		
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 3		
Blood bilirubin increased subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 3		
Blood creatinine increased subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 6		
Blood lactate dehydrogenase increased			

subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Lymphocyte count decreased subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 4		
Neutrophil count decreased subjects affected / exposed occurrences (all)	10 / 33 (30.30%) 19		
Platelet count decreased subjects affected / exposed occurrences (all)	9 / 33 (27.27%) 9		
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Serum ferritin increased subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Weight decreased subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 4		
White blood cell count decreased subjects affected / exposed occurrences (all)	8 / 33 (24.24%) 8		
Injury, poisoning and procedural complications Infusion related reaction subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Tachycardia subjects affected / exposed occurrences (all)	4 / 33 (12.12%) 4		
Nervous system disorders			



Depressed level of consciousness subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Dizziness subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 3		
Headache subjects affected / exposed occurrences (all)	8 / 33 (24.24%) 11		
Neuralgia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Neuropathy peripheral subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Paraesthesia subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	11 / 33 (33.33%) 18		
Bone marrow failure subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Coagulopathy subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Febrile neutropenia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Leukopenia subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 7		
Lymphopenia			

subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Neutropenia			
subjects affected / exposed	7 / 33 (21.21%)		
occurrences (all)	11		
Thrombocytopenia			
subjects affected / exposed	4 / 33 (12.12%)		
occurrences (all)	4		
Eye disorders			
Vision blurred			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	3		
Abdominal pain			
subjects affected / exposed	6 / 33 (18.18%)		
occurrences (all)	9		
Abdominal pain upper			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Constipation			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	3		
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Lower gastrointestinal haemorrhage			
subjects affected / exposed	2 / 33 (6.06%)		
occurrences (all)	2		
Nausea			
subjects affected / exposed	9 / 33 (27.27%)		
occurrences (all)	13		
Small intestinal obstruction			

subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Stomatitis subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 6		
Vomiting subjects affected / exposed occurrences (all)	13 / 33 (39.39%) 19		
Hepatobiliary disorders Cholelithiasis subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Dry skin subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Pruritus subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Rash subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 3		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Neck pain subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Pain in extremity subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Infections and infestations			

Myelitis subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 6		
Hyperphosphataemia subjects affected / exposed occurrences (all)	3 / 33 (9.09%) 3		
Hypomagnesaemia subjects affected / exposed occurrences (all)	4 / 33 (12.12%) 4		
Hyponatraemia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Hypophosphataemia subjects affected / exposed occurrences (all)	2 / 33 (6.06%) 2		
Hypokalaemia subjects affected / exposed occurrences (all)	5 / 33 (15.15%) 5		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 January 2020	Update of inclusion criteria to allow patients between 18 and 25 years of age; Update inclusion criteria to allow Burkitt leukemia; Addition of a data monitoring committee for safety monitoring; Removed absolute lymphocyte count and absolute CD3+ T cell requirements from inclusion criteria

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use <https://www.novctrd.com/CtrdWeb/home.nov> for complete trial results

Notes: